Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $178000.0.

  • Lineage Cell Therapeutics' Depreciation & Amortization (CF) rose 2624.11% to $178000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $664000.0, marking a year-over-year increase of 1468.05%. This contributed to the annual value of $587000.0 for FY2024, which is 444.84% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Depreciation & Amortization (CF) of $178000.0 as of Q3 2025, which was up 2624.11% from $171000.0 recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $178000.0 for Q3 2025, and its period low was $138000.0 during Q1 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' median Depreciation & Amortization (CF) value was $150000.0 (recorded in 2022), while the average stood at $153000.0.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Depreciation & Amortization (CF) crashed by 2190.48% in 2021 and then surged by 2624.11% in 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $159000.0 in 2021, then decreased by 11.32% to $141000.0 in 2022, then increased by 1.42% to $143000.0 in 2023, then rose by 5.59% to $151000.0 in 2024, then grew by 17.88% to $178000.0 in 2025.
  • Its last three reported values are $178000.0 in Q3 2025, $171000.0 for Q2 2025, and $164000.0 during Q1 2025.